<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2707">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 18, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04750759</url>
  </required_header>
  <id_info>
    <org_study_id>201741</org_study_id>
    <nct_id>NCT04750759</nct_id>
  </id_info>
  <brief_title>Safety and Preliminary Efficacy of the Combination of Niclosamide and Camostat</brief_title>
  <acronym>NICCAM</acronym>
  <official_title>A Randomized, Single Blind, Placebo-controlled, Multiple Dose, Parallel-arm Study to Investigate the Safety and Preliminary Efficacy of the Combination of Niclosamide and Camostat to Treat COVID-19 (&quot;NICCAM&quot;)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charité Research Organisation GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Charité Research Organisation GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Niclosamide (2000 mg QD) and Camostate (600 mg QID) are expected to be safe and&#xD;
      well-tolerated as a combination therapy and to show clinically beneficial for COVID-19&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Niclosamide is an approved drug for the treatment of intestinal worm infections that can&#xD;
      potentially induce the process of autophagy and thus significantly limit viral replication in&#xD;
      cells.&#xD;
&#xD;
      Camostat is approved in Japan for the treatment of chronic pancreatitis and reflux&#xD;
      esophagitis. It has been shown to effectively block viral replication in a SARS-CoV-2 animal&#xD;
      model.&#xD;
&#xD;
      Since the mechanisms of actions are different, it was hypothesized that a combination of both&#xD;
      substances might have an additive or even synergistic effect in the treatment of patients&#xD;
      with COVID-19.&#xD;
&#xD;
      This study is designed to investigate the safety, tolerability and preliminary efficacy of&#xD;
      the treatment combination niclosamide and camostat in mild and moderately affected COVID-19&#xD;
      patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment emergent number of Adverse Events</measure>
    <time_frame>21 days</time_frame>
    <description>All pathological and clinically significant findings in physical examinations, vital signs, 12-lead ECGs, oxygen saturation and safety lab including coagulation will be documented as adverse events. Adverse events will be reported on the basis of CTCAE v5.0.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Niclosamide + Camostat</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive the combination of niclosamide chewing tablets (2000 mg, once daily) and camostat tablets (600 mg, 4-times daily) over a period of 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive placebo orally over a period of 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niclosamide + Camostat</intervention_name>
    <description>Niclosamide will be applied in combination with camostat.</description>
    <arm_group_label>Niclosamide + Camostat</arm_group_label>
    <other_name>Yomesan</other_name>
    <other_name>Foipan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to interventional drug</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients in the age of 18 to 70 years&#xD;
&#xD;
          -  Having a recent positive direct test for Sars-CoV-2&#xD;
&#xD;
          -  Having mild or moderate COVID-19 symptoms with no indication for hospitalization due&#xD;
             to SARS-CoV-2 infection (WHO Ordinal Scale 1-2)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe respiratory symptoms related to COVID-19 requiring oxygen or intensive care&#xD;
             (high flow oxygen or mechanical ventilation or ECMO)&#xD;
&#xD;
          -  Patients with preexisting pulmonary diseases requiring oxygen supply&#xD;
&#xD;
          -  Patients with history of hypersensitivity to Camostat or Niclosamide or to any&#xD;
             ingredients to any of the two drugs&#xD;
&#xD;
          -  Patients with heart failure (NYHA III or NYHA IV)&#xD;
&#xD;
          -  Patients with proven malignant tumor&#xD;
&#xD;
          -  Patients diagnosed with influenza infection&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Immunocompromised patients&#xD;
&#xD;
          -  Creatinine clearance &lt; 60 mL/min&#xD;
&#xD;
          -  aspartate aminotransferase (AST) / alanine aminotransferase (ALT) &gt; 2 times upper&#xD;
             limit of normal (ULN)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Witzenrath, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frank D. Wagner, Prof.</last_name>
    <phone>+49 30 450 539 200</phone>
    <email>info@charite-research.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Charité Research Organisation GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Witzenrath, Prof.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 8, 2021</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2021</study_first_posted>
  <last_update_submitted>February 17, 2021</last_update_submitted>
  <last_update_submitted_qc>February 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niclosamide</mesh_term>
    <mesh_term>Camostat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

